Down 18.3% in 4 Weeks, Here's Why Soleno Therapeutics (SLNO) Looks Ripe for a Turnaround

Core Viewpoint - Soleno Therapeutics, Inc. (SLNO) has experienced significant selling pressure, resulting in an 18.3% decline in stock price over the past four weeks, but analysts anticipate improved earnings in the near future [1] Group 1: Technical Analysis - The Relative Strength Index (RSI) is utilized to determine if SLNO is oversold, with a current reading of 28.79 indicating potential for a trend reversal [2][5] - RSI serves as a momentum oscillator that helps identify price movement changes, suggesting that SLNO may be undervalued due to excessive selling pressure [3] Group 2: Fundamental Analysis - Analysts have raised earnings estimates for SLNO by 7.8% over the last 30 days, indicating a positive trend that typically correlates with stock price appreciation [7] - SLNO holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks, further supporting the potential for a near-term turnaround [8]